PRPleun J. de Raaf

Pleun J. de Raaf

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pleun J. de Raaf has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Carin C.D. van der Rijt

    Pleun J. de Raaf, Wendy H. Oldenmenger, and Carin C.D. van der Rijt, Daniel den Hoed Cancer Center; Pleun J. de Raaf, Cora de Klerk, Reinier Timman, and Jan J.V. Busschbach, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, the Netherlands

    2 shared publications
  • Cora de Klerk

    Pleun J. de Raaf, Wendy H. Oldenmenger, and Carin C.D. van der Rijt, Daniel den Hoed Cancer Center; Pleun J. de Raaf, Cora de Klerk, Reinier Timman, and Jan J.V. Busschbach, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, the Netherlands

    2 shared publications
  • Reinier Timman

    Pleun J. de Raaf, Wendy H. Oldenmenger, and Carin C.D. van der Rijt, Daniel den Hoed Cancer Center; Pleun J. de Raaf, Cora de Klerk, Reinier Timman, and Jan J.V. Busschbach, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, the Netherlands

    2 shared publications
  • Agnes Jager

    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, the Netherlands

    1 shared publication
  • Andreas Hinz

    1 shared publication
  • C. C. D. van der Rijt

    Department of Medical Oncology, Daniel den Hoed Cancer Center Erasmus MC Rotterdam The Netherlands

    1 shared publication

Latest Publications

  • Systematic Monitoring and Treatment of Physical Symptoms to Alleviate Fatigue in Patients With Advanced Cancer: A Randomized Controlled Trial

    by Pleun J. de Raaf, Cora de Klerk, Reinier Timman, Jan J.V. Busschbach, Wendy H. Oldenmenger, Carin C.D. van der Rijt

    Purpose Several guidelines on the treatment of cancer-related fatigue recommend optimizing treatment of accompanying symptoms. However, evidence for this recommendation from randomized clinical trials is lacking. We investigated whether monitoring and protocolized treatment of physical symptoms alleviates fatigue. Patients and Methods In all, 152 fatigued patients with advanced cancer were randomly assigned to protocolized patient-tailored treatment (PPT) of symptoms or care as usual. The PPT group had four appointments with a nurse who assessed nine symptoms on a 0 to 10 numeric rating scale (NRS). Patients received a nonpharmacologic intervention for symptoms with a score ≥ 1 and a medical intervention for symptoms with a score ≥ 4. Fatigue dimensions, fatigue NRS score, interference of fatigue with daily life, symptom burden, quality of life, anxiety, and depression were measured at baseline and after 1, 2, and 3 months. Differences between the groups over time were assessed by using mixed modeling. Results Seventy-six patients were randomly assigned to each study arm. Mean age was 58 ± 10 years, 57% were female, and 65% were given palliative chemotherapy. We found significant improvements over time in favor of PPT for the primary outcome general fatigue (P = .01), with significant group differences at month 1 (effect size, 0.26; P = .007) and month 2 (effect size, 0.35; P = .005). Improvements in favor of PPT were also found for the following secondary outcomes: fatigue dimensions “reduced activity” and “reduced motivation,” fatigue NRS, symptom burden, interference of fatigue with daily life, and anxiety (all P ≤ .03). Conclusion In fatigued patients with advanced cancer, nurse-led monitoring and protocolized treatment of physical symptoms is effective in alleviating fatigue.


  • Elucidating the behavior of physical fatigue and mental fatigue in cancer patients: a review of the literature

    by P. J. de Raaf, C. de Klerk, C. C. D. van der Rijt

    Background: Although the multidimensional nature of cancer‐related fatigue is widely accepted, it could be questioned whether fatigue dimensions are expressions of one symptom (multidimensional concept) or expressions of several phenomena that are all called fatigue but actually are separate symptoms (multiple‐symptom concept).Methods: Therefore, we investigated in this review whether physical fatigue and mental fatigue behave differently in cancer patients by studying their intensity in different stages of cancer, their changes in intensity during anti‐tumor therapy, the variables to which they are related, and their changes in intensity by interventions on fatigue.Results: In some studies, physical fatigue and mental fatigue behaved similarly: they were both more intense in cancer patients than in healthy controls, and sometimes, they had the same course during anti‐tumor therapy, or both improved during an intervention. On the contrary, there were some studies suggesting that physical fatigue and mental fatigue behaved differently: physical fatigue seemed to be more prominent than mental fatigue in some stages of the disease trajectory; several studies reported changes in physical fatigue not accompanied by changes in mental fatigue during anti‐tumor therapy or by interventions aimed to relieve fatigue; and physical fatigue and mental fatigue had different correlates.Conclusions: In conclusion, we found some studies in which physical fatigue and mental fatigue behaved differently. These findings might indicate that physical fatigue and mental fatigue are separate phenomena. To prove this multiple‐symptom concept, studies on the pathophysiological mechanisms leading either to physical fatigue or to mental fatigue are urgently needed. Copyright © 2012 John Wiley & Sons, Ltd.


  • Open Access

    Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors

    by Pleun J. de Raaf, Stefan Sleijfer, Cor H.J. Lamers, Agnes Jager, Jan Willem Gratama, Carin C. D. van der Rijt

    BACKGROUND: Inflammation may underlie cancer‐related fatigue; however, there are no studies that assess the relation between fatigue and cytokines in patients with advanced disease versus patients without disease activity. Furthermore, the relation between cytokines and the separate dimensions of fatigue is unknown. Here, association of plasma levels of inflammatory markers with physical fatigue and mental fatigue was explored in advanced cancer patients and cancer survivors.METHODS: A total of 45 advanced cancer patients and 47 cancer survivors completed the subscales Physical Fatigue and Mental Fatigue of the Multidimensional Fatigue Inventory. Plasma concentrations of C‐reactive protein (CRP), interleukin‐1 receptor antagonist (IL‐1‐ra), interleukin‐6 (IL‐6), interleukin‐8 (IL‐8), and neopterin were measured. Nonparametric tests were used to assess differences in fatigue intensity and levels of inflammatory markers and to determine correlation coefficients between the fatigue dimensions and inflammatory markers.RESULTS: Compared with cancer survivors, patients with advanced cancer had higher levels of physical fatigue (median 16 vs 9, P < .001) and mental fatigue (median 11 vs 6, P = .01). They also had higher levels of all cytokines (P < .01). In advanced cancer, CRP (r = 0.49, P = .001), IL‐6 (r = 0.43, P = .003), IL‐1‐ra (r = 0.32, P = .03), and neopterin (r = 0.25, P = .10) were correlated with physical but not with mental fatigue. In cancer survivors, only IL‐1‐ra was related to both physical fatigue (r = 0.24, P = .10) and mental fatigue (r = 0.35, P = .02).CONCLUSIONS: In advanced cancer, inflammation seems to be associated with physical fatigue, but not to mental fatigue. In cancer survivors, there was no convincing evidence that inflammation plays a major role in fatigue. Cancer 2012. © 2012 American Cancer Society.